Evaluating

Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz…

The treatment combines Clearmind's MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™ Tel Aviv, Israel / Vancouver,…

- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) - - DDLPS expansion cohort…

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan…

EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) --…

Preclinical data demonstrates that LGR5-targeting CAR-T therapy…

With this strategic effort, HARMAN is tapping into ACM’s real-world driving environments equipped with connected infrastructure and Multi-access Edge Computing (MEC) services for evaluating road-ready connected vehicle products through 5G…

Initial report ranks top 10 last-mile delivery companies based on Level of Innovation and Market Potential NEW YORK--(BUSINESS WIRE)--Coresight Research (Coresight) announces the launch of the Innovator Matrix report series. Coresight is…

<!-- Name:DistributionId Value:1000780622 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value: -->…

SAN FRANCISCO, Dec. 19, 2022 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the enrollment of the first…